Latest news with #Co-Diagnostics
Yahoo
14-05-2025
- Business
- Yahoo
Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the 'Company' or 'Co-Dx'), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital ('DBC') Inaugural Global Conference on May 14, 2025 in New York City. The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company's value proposition and to the upcoming Co-Dx PCR* testing platform. More information about the conference can be found here. *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale. About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease. Please note that we disclaim any responsibility for the content of external links provided in this press release. These links are provided solely for the reader's convenience and do not constitute an endorsement by the Company. Company Contact: Andrew Benson Head of Investor Relations +1.801.438.1036 investors@
Yahoo
29-03-2025
- Business
- Yahoo
Co-Diagnostics Full Year 2024 Earnings: Misses Expectations
Net loss: US$37.6m (loss widened by 6.5% from FY 2023). US$1.24 loss per share (further deteriorated from US$1.20 loss in FY 2023). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 1.6%. The company's shares are down 31% from a week ago. You still need to take note of risks, for example - Co-Diagnostics has 6 warning signs (and 2 which are potentially serious) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
